- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GILD
Recent news which mentions GILD
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
April 04, 2022
Tickers
GILD
From Benzinga
10 Biggest Price Target Changes For Monday
April 04, 2022
From Benzinga
Gilead's Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma
April 04, 2022
Tickers
GILD
From Benzinga
2 Drugmakers Set for Explosive Revenue This Decade
April 03, 2022
From Motley Fool
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
From Benzinga
From Motley Fool
Investors Seek Second Act with Moderna Stock
March 29, 2022
From InvestorPlace
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
March 28, 2022
From Benzinga
2 High-Yielding Stocks Trading Near Multiyear Lows
March 23, 2022
From Motley Fool
10 Biggest Price Target Changes For Monday
March 22, 2022
From Benzinga
From Benzinga
From Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
March 11, 2022
Tickers
GILD
From Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
From Benzinga
A Peek Into The Markets: US Stock Futures Tumble Following New Sanctions Against Russia
February 28, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
3 Pharma Stocks That Retired Investors Should Love
February 26, 2022
From Motley Fool
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
From InvestorPlace
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
From InvestorPlace
See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization
February 18, 2022
From Benzinga
Want To Collect $200 Every Month? Invest $49,334 in These 3 Stocks
February 18, 2022
From Motley Fool
These 3 Stocks Just Declared Dividend Raises
February 18, 2022
From Motley Fool
Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients
February 17, 2022
Tickers
GILD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.